Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.73 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.61 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.61 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.61 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23124024 | 0.98 | CCR3 (0.71) | CCR3ACHEPRMT3CARM1PRMT6 | |
| SCHEMBL10447127 | 0.94 | CCR3 (0.65) | CCR3ACHEPRMT3CARM1PRMT6 | |
| SCHEMBL5779205 | 0.90 | CCR3 (0.64) | CCR3ACHEPRMT3CARM1PRMT6 | |
| SCHEMBL5365334 | 0.90 | SIGMAR1 (0.68) | CCR3SIGMAR1 | |
| SCHEMBL5368437 | 0.89 | SIGMAR1 (0.75) | CCR3SIGMAR1 | |
| SCHEMBL10446739 | 0.87 | CCR3 (0.69) | CCR3ACHEPRMT3CARM1PRMT6 | |
| SCHEMBL29381887 | 0.84 | CCR3 (0.75) | CCR3ACHECARM1PRMT6 | |
| SCHEMBL7403790 | 0.84 | CCR3 (1.00) | CCR3ACHEPRMT3CARM1PRMT6 | |
| SCHEMBL3600688 | 0.83 | HTR2A (0.57) | — | |
| SCHEMBL22254776 | 0.83 | HRH3 (0.62) | CCR3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230002356-A1 | COMPOUNDS AND USES THEREOF | PANO THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| CN-111629728-A | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | 科尔沃斯制药股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2017109061-A1 | SPIROCYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2017-06-29 | — | — | WO | disclosed |
| US-8507528-B2 | 2-alkyl-indazole compounds for the treatment of certain cns-related disorders | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-08-13 | — | — | US | disclosed |
| CN-101558057-B | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | ACRAF | 2013-05-01 | — | — | CN | disclosed |
| US-8415476-B2 | Indazole having analgesic activity | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-04-09 | — | — | US | disclosed |
| EP-2099780-B1 | 2 -ALKYL- INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | ACRAF (IT) | 2013-01-09 | — | — | EP | disclosed |
| US-20100094015-A1 | INDAZOLE HAVING ANALGESIC ACTIVITY | AZIENDE CHIM. RIUN. ANGEL. FRA. A.C.R.A.F. S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| EP-1390034-A4 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1390034-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| US-5480892-A | SIGMA RECEPTOR ANTAGONISTS; TREATMENT OF PHYSIOLOGICAL OR DRUG INDUCED PSYCHOSIS AND DYSKINESIA | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| US-5356906-A | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| WO-1993022310-A1 | (N-PHTHALIMIDOALKYL)PIPERIDINES FOR THE TREATMENT OF PSYCHOSES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0497843-A4 | (N-PHTHALIMIDOALKYL) PIPERIDINES | — | 1992-09-23 | — | — | EP | disclosed |
| EP-0497843-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006297-A1 | (N-PHTHALIMIDOALKYL) PIPERIDINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-05-16 | — | — | WO | disclosed |
| EP-0343307-A1 | 4-Piperidinealkanamine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056573-A1 | 2-ALKYL-INDAZOLE COMPOUNDS FOR THE TREATMENT OF CERTAIN CNS-RELATED DISORDERS | CYP11B2, CYP1A2, INA | CCR3 2769/4885ACHE 621/4885PRMT3 285/4885 |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | CCR3 1281/4885ACHE 844/4885PRMT3 1819/4885 |
| US-20100094015-A1 | INDAZOLE HAVING ANALGESIC ACTIVITY | OPRK1, OPRD1, ACHE | CCR3 870/4885ACHE 3/4885PRMT3 2430/4885 |
| US-20230002356-A1 | COMPOUNDS AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | CCR3 3574/4885ACHE 4090/4885PRMT3 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.